In fact, survival of PV was more sensitive than AB not only to JAK/STAT inhibitors but also to inhibitors of cKIT and MEK (which is upstream of ERK1/2) and of CD63 suggesting that further endeavors to treat the disease should be focused either on MEK inhibitors or CD63 antibodies (53). This evidence concerns the gene MAPK3 and acquired polycythemia vera.